Comparative Pharmacology
Head-to-head clinical analysis: SODIUM SULFACETAMIDE versus SULFONAMIDES DUPLEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SODIUM SULFACETAMIDE versus SULFONAMIDES DUPLEX.
SODIUM SULFACETAMIDE vs SULFONAMIDES DUPLEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfacetamide is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, thereby blocking the synthesis of folic acid and ultimately nucleic acid synthesis, leading to bacteriostatic activity.
Sulfonamides are competitive antagonists of para-aminobenzoic acid (PABA) and inhibit dihydropteroate synthase, blocking folate synthesis in susceptible bacteria.
1-2 drops of 10% or 30% solution into conjunctival sac every 2-3 hours during waking hours for 7-10 days.
Oral: 500-1000 mg twice daily; maximum 2000 mg/day.
None Documented
None Documented
7-12 hours in normal renal function; prolonged to 20-50 hours in renal impairment.
Terminal half-life: 7-12 hours in patients with normal renal function; prolonged to 24-50 hours in renal impairment (CrCl <30 mL/min) due to reduced elimination.
Renal: 85-100% unchanged drug via glomerular filtration and tubular secretion. Biliary/fecal: <5%.
Renal: 70-100% unchanged drug via glomerular filtration and tubular secretion; fecal/biliary: <5%.
Category A/B
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic